Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer

EP: 1.Diagnosis and Risk Stratification for Early-Stage HR+/HER2- Breast Cancer

EP: 2.CDK4/6 Inhibitors for HR+/HER2- Early Breast Cancer

EP: 3.Current Practices for Targeted Therapies and Molecular Testing for HR+/HER2- Metastatic Breast Cancer

EP: 4.Exploring 1L and 2L CDK4/6 Inhibitors + Endocrine Therapies

EP: 5.Clinical Perspectives: Use of CDK4/6i After CDK4/6i

EP: 6.The Current Treatment Landscape of Oral SERDs in Metastatic Breast Cancer

EP: 7.Clinical Findings of Elacestrant, an Oral SERD for ER+/HER2– Metastatic Breast Cancer

EP: 8.Emerging Data of Additional SERDs in Metastatic Breast Cancer

EP: 9.CDK4/6 Inhibitors Plus Novel Agents for ER+/HER2–Advanced or mBC

EP: 10.Toxicities and Treatment Selection of Endocrine-Based Therapies in HR+/HER2– Breast Cancer

Now Viewing

EP: 11.Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer

EP: 12.Exploring Data of PI3K/AKT/mTOR Inhibitors in HER2– mBC

EP: 13.Clinical Developments of Antibody-Drug Conjugates (ADCs) in HR+/HER2– mBC

EP: 14.ADCs: Recent Data of Dato-DXd from TROPION-Breast01

EP: 15.Impact of ADC Toxicities and Clinical Decision-Making for mBC

EP: 16.Continued Advances and Treatment Sequencing for HR+/HER2– Breast Cancer

Video content above is prompted by the following:

Dr. Bardia to Dr. Chan:What are the more genotype-directed options for advanced HR+/HER2–- disease (PI3K/AKT/mTOR inhibitors, ADCs, etc.)?

How, and for what patient populations, are these being used based on the most recent data? What are your impressions of each of these regimens?

Inavolisib – How might the recent first-line inavolisib approval change the treatment paradigm? (approved in combination with palbociclib and fulvestrant for patients withPI3K-mutated, HR+, HER2–- la /metastatic breast cancer mBC that whoprogress on or relapse within 12 months after completing adjuvant endocrine therapy)change the treatment paradigm?